Literature DB >> 17043123

Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers.

Takahiro Shibayama1, Yoko Matsushita, Takashi Hirota, Toshihiko Ikeda, Shogo Kuwahara.   

Abstract

The CS-023 concentration in plasma after administration by infusion to healthy volunteers at a dose of 700 mg was decreased, with a half-life of 1.7 h, and the cumulative urinary excretion was 59.4% of the dose. The total clearance, renal clearance, and volume of distribution were 8.12 liters/h, 4.14 liters/h, and 17.2 liters, respectively.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17043123      PMCID： PMC1694003          DOI： 10.1128/AAC.00494-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Prevention of resistance: a goal for dose selection for antimicrobial agents.

Authors:  G L Drusano
Journal:  Clin Infect Dis       Date:  2003-01-15       Impact factor: 9.079

3.  CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa.

Authors:  Kenneth S Thomson; Ellen Smith Moland
Journal:  J Antimicrob Chemother       Date:  2004-06-16       Impact factor: 5.790

4.  Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates.

Authors:  J G Sundelof; R Hajdu; C J Gill; R Thompson; H Rosen; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 5.  Physiological parameters in laboratory animals and humans.

Authors:  B Davies; T Morris
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

6.  The pharmacokinetics of meropenem in volunteers.

Authors:  R P Bax; W Bastain; A Featherstone; D M Wilkinson; M Hutchison; S J Haworth
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

Review 7.  The pharmacology of meropenem, a new carbapenem antibiotic.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

8.  Synthesis and structure-activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety.

Authors:  Isao Kawamoto; Yasuo Shimoji; Osamu Kanno; Katsuhiko Kojima; Katsuya Ishikawa; Emi Matsuyama; Yuka Ashida; Takahiro Shibayama; Takashi Fukuoka; Satoshi Ohya
Journal:  J Antibiot (Tokyo)       Date:  2003-06       Impact factor: 2.649

Review 9.  An overview of the pharmacology of imipenem/cilastatin.

Authors:  G L Drusano
Journal:  J Antimicrob Chemother       Date:  1986-12       Impact factor: 5.790

10.  Pharmacokinetic profile of imipenem/cilastatin in normal volunteers.

Authors:  G L Drusano; H C Standiford
Journal:  Am J Med       Date:  1985-06-07       Impact factor: 4.965
View more
  7 in total

1.  In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.

Authors:  Kiyoshi Sugihara; Chika Sugihara; Yoko Matsushita; Naotoshi Yamamura; Mitsutoshi Uemori; Akane Tokumitsu; Harumi Inoue; Masayo Kakuta; Eiko Namba; Hatsumi Nasu; Tetsufumi Koga
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Efficacy of human-simulated exposures of tomopenem (formerly CS-023) in a murine model of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus infection.

Authors:  Kiyoshi Sugihara; Kazuhiro Tateda; Naotoshi Yamamura; Tetsufumi Koga; Chika Sugihara; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

3.  In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.

Authors:  Kaori Tanaka; Hiroshige Mikamo; Kenichi Nakao; Taku Ichiishi; Takatsugu Goto; Yuka Yamagishi; Kunitomo Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

4.  Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.

Authors:  Navita L Mallalieu; Siân Lennon; Mei Liu; Christopher Kirkpatrick; Richard Robson; Eric Luedin; Brian E Davies
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

5.  Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Tetsufumi Koga; Nobuhisa Masuda; Masayo Kakuta; Eiko Namba; Chika Sugihara; Takashi Fukuoka
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

6.  Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.

Authors:  Alasdair P MacGowan; Karen E Bowker; Alan R Noel
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

Review 7.  Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.

Authors:  Despoina Koulenti; Elena Xu; Andrew Song; Isaac Yin Sum Mok; Drosos E Karageorgopoulos; Apostolos Armaganidis; Sotirios Tsiodras; Jeffrey Lipman
Journal:  Microorganisms       Date:  2020-01-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.